STADA Premium Quality Aromasin(Exemestane) 25mg*50

STADA Premium Quality Aromasin(Exemestane) 25mg*50
Product Introduction:
STADA Aromasin (Exemestane) tablets 25mg are a third-generation steroidal aromatase inhibitor for oral use, mainly used to treat hormone receptor-positive breast cancer patients, especially for postmenopausal women. The drug irreversibly inhibits aromatase and blocks the conversion of androgens to estrogens, thereby significantly reducing estrogen levels in the body and inhibiting tumor growth and spread. Each tablet contains 25mg of Exemestane, and is a white or off-white round tablet. It is usually taken orally once a day, and it is recommended to be taken with food to improve absorption. As a well-known pharmaceutical brand, STADA has stable product quality, long-lasting efficacy, and relatively controllable side effects. Common adverse reactions include hot flashes, joint pain, fatigue, and mild bone loss. Aromasin not only performs well in adjuvant treatment of breast cancer, but is also often used in the field of bodybuilding to help control estrogen levels in the body and prevent side effects after steroid use such as edema and estrogen-induced accessory breasts. Since long-term use may increase the risk of osteoporosis, patients are usually advised to undergo regular bone density tests and reasonably supplement calcium and vitamin D according to the doctor's advice.
Send Inquiry
Description
Technical Parameters

 

 

Introduction

 

pill

1

2

2

product-1400-1400

 

Products Description

 

### Systematic introduction of STADA Aromasin (Exemestane) 25mg tablets

#### 1. Drug Overview

**STADA Aromasin** (chemical name: Exemestane) is an oral aromatase inhibitor (AI), mainly used to treat hormone receptor-positive breast cancer in postmenopausal women. The drug inhibits the activity of aromatase and blocks estrogen synthesis, thereby inhibiting the growth of estrogen-dependent tumors. As an internationally renowned generic drug company, STADA's Exemestane tablets are known for their high bioequivalence and economy and are widely used in clinical practice.

---

#### 2. Pharmacological properties

1. **Mechanism of action**

Exemestane inhibits the conversion of androgens to estrogens and reduces estrogen levels in the body by irreversibly binding to aromatase (CYP19A1). Its action is highly selective and has no significant effect on adrenal cortical hormone synthesis.

2. **Pharmacodynamic advantages**

- **Potency**: Clinical data show that exemestane can reduce estrogen levels by 85%-95%.

- **Irreversible inhibition**: Compared with reversible inhibitors (such as anastrozole), exemestane has a long-lasting effect and needs to rely on new enzyme synthesis to restore activity.

- **Low cross-resistance**: Suitable for patients resistant to other AIs.

---

#### 3. Indications and clinical applications

1. **Main indications**

- Adjuvant treatment of advanced breast cancer in postmenopausal women.

- Postoperative adjuvant treatment of early breast cancer (especially for patients resistant to tamoxifen).

- Combined with ovarian inhibitors for hormone therapy in premenopausal women.

2. **Usage and Dosage**

- **Standard dose**: Once a day, 25 mg each time, taken after meals to increase absorption.

- **Dose adjustment**: Patients with hepatic and renal insufficiency do not need to adjust the dose, but need to be closely monitored.

---

#### 4. Physical and chemical properties

1. **Chemical structure**

Exemestane (C20H24O2) is a steroidal compound with a chemical name of 6-methylandrost-1,4-diene-3,17-dione and a molecular weight of 296.4 g/mol.

2. **Physical and chemical parameters**

- **Solubility**: Highly lipid-soluble, extremely low solubility in water (<0.1 mg/mL), easily soluble in organic solvents such as ethanol.

- **Stability**: Light-sensitive, needs to be stored away from light; stable in an acidic environment, with a degradation rate of <5% at pH 1-4.

- **Melting point**: 195-198°C.

3. **Preparation characteristics**

- **Tablet type**: Film-coated tablets to improve stability and taste-masking effects.

- **Excipient ingredients**: Contains microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, magnesium stearate, etc., to optimize disintegration and dissolution rates.

---

#### 5. Dosage form and appearance

1. **Tablet specifications**

- **Dosage**: 25 mg/tablet.

- **Packaging**: 14 tablets/box or 28 tablets/box are common, which can meet the needs of different treatment courses.

2. **Appearance characteristics**

- **Color**: STADA Aromasin tablets are usually white to off-white film-coated tablets with double-sided convexity.

- **Score**: Some batches may contain a central score to facilitate dose division (please follow the doctor's advice).

- **Mark**: "EXE 25" or manufacturer-specific code is printed on the surface of the tablet for easy identification.

---

#### 6. Clinical advantages and patient benefits

1. **Efficacy advantages**

- **Improved survival rate**: The MA-27 trial showed that the 5-year disease-free survival rate of adjuvant exemestane therapy was 3.3% higher than that of tamoxifen.

- **Bone safety**: Compared with non-steroidal AI (such as letrozole), steroidal exemestane has less effect on bone density.

2. **Tolerability**

- **Side effect spectrum**: Common hot flashes (20%-30%), joint pain (15%-20%), severe hepatotoxicity incidence <1%.

- **Fewer drug interactions**: Mainly metabolized by CYP3A4, no significant interaction with warfarin and digoxin.

3. **Economical**

- As a generic drug, the price of STADA brand is 30%-50% lower than that of the original drug, reducing the economic burden on patients.

---

#### 7. Pharmacokinetics

1. **Absorption**

- **Bioavailability**: About 42%, eating a high-fat meal can increase the absorption rate by 40%.

- **Peak time**: 2-3 hours.

2. **Distribution**

- **Protein binding rate**: 90%, mainly bound to albumin.

- **Tissue penetration**: It can penetrate the blood-brain barrier, and the concentration in cerebrospinal fluid is about 10% of that in plasma.

3. **Metabolism and excretion**

- **Metabolic pathway**: CYP3A4 mediates oxidative metabolism to produce inactive metabolites.

- **Half-life**: 24 hours, supporting once-daily dosing.

- **Excretion pathway**: About 42% is excreted through urine and 42% through feces.

---

#### 8. Safety and adverse reaction management

1. **Common adverse reactions**

- **Endocrine system**: Hot flashes, night sweats.

- **Musculoskeletal**: Arthralgia, osteoporosis (incidence of about 10%).

- **Gastrointestinal**: Nausea, diarrhea (usually mild).

2. **Serious risk warning**

- **Cardiovascular events**: Rare myocardial ischemia (<0.1%).

- **Liver enzyme elevation**: It is recommended to monitor liver function every 3 months in the early stage of treatment.

3. **Contraindications**

- Premenopausal women, pregnant women, and those who are allergic to drug ingredients are prohibited.

---

#### 9. Drug interactions

1. **CYP3A4 inducers** (such as rifampicin, phenytoin): may reduce the blood concentration of exemestane, and should be used with caution.

2. **Estrogen drugs**: antagonize the efficacy of exemestane, and are prohibited from being used together.

3. **Anticoagulants**: There is no direct interaction, but INR values ​​need to be monitored (increased bleeding risk has been reported in individual cases).

---

#### 10. Storage and stability

- **Temperature**: Store below 25°C and avoid freezing.

- **Humidity**: Relative humidity <60%, need to be sealed to prevent moisture.

- **Expiration date**: 36 months in unopened state, it is recommended to use up within 6 months after opening.

---

#### 11. Key points for patient education

1. **Medication compliance**: Take the medicine at a fixed time every day. Do not take a double dose after missing a dose.

2. **Lifestyle**: It is recommended to supplement calcium (1200 mg/day) and vitamin D (800 IU/day) to prevent osteoporosis.

3. **Follow-up monitoring**: Evaluate bone density every 6 months and perform breast imaging every year.

---

#### 12. Market and production information

1. **Manufacturer**: STADA Arzneimittel AG, a German listed pharmaceutical company, certified by WHO-GMP.

2. **Global listing**: Approved in many countries in Europe and Asia, and will be included in the Chinese centralized procurement catalog in 2020.

3. **Quality control**: High performance liquid chromatography (HPLC) is used to detect dissolution (30-minute dissolution > 85%), which meets USP standards.

---

### Conclusion

STADA Aromasin 25mg tablets have balanced efficacy, safety and economy through optimized preparation process and strict quality control, becoming an important choice for endocrine therapy of breast cancer. In clinical use, it is necessary to combine the individual characteristics of patients and formulate long-term management strategies to achieve the best treatment outcomes.

 

 

Supported Payment Methods And Contact Us

 

Supported payment methods
 
 

We support multiple payment methods

17394303381961
17394301727501
aee89153b2c364c4e2c2b8f949c7034
product-124-136
product-150-133
 
Contact Us
 
 

You can contact us via WhatsApp, Telegram, Gmail, Proton Mail, etc.

Whatsapp
Telegram
Gmail
11111111111
Skype

Contact Us Now By Email

 

 

 

 

 

 

 

 

 

Hot Tags: stada premium quality aromasin(exemestane) 25mg*50, China stada premium quality aromasin(exemestane) 25mg*50 manufacturers, suppliers, factory, Dianabol, Halotestin Dramatically improve strength, Winstrol Makes muscle lines more clear, Clomid CAS 50 41 9, Halotestin, Dianabol Rapid muscle growth and improved condition

Send Inquiry
Auctus Steroid Pharma Co., Ltd
Provide a complete after-sales service guarantee, including product return and exchange policies, quality assurance, etc.
contact us